Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma

BACKGROUND: Pediatric patients with high-risk neuroblastoma (HR NB) often fail to respond to upfront intensive multimodal therapy. Tumor-acquired suppression of apoptosis contributes to therapy resistance. Many HR NB tumors depend on the anti-apoptotic protein Bcl-2 for survival, through Bcl-2 seque...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanos, Rachel, Karmali, Dipan, Nalluri, Srilatha, Goldsmith, Kelly C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752777/
https://www.ncbi.nlm.nih.gov/pubmed/26874859
http://dx.doi.org/10.1186/s12885-016-2129-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752777/
https://www.ncbi.nlm.nih.gov/pubmed/26874859
http://dx.doi.org/10.1186/s12885-016-2129-0

Ejemplares similares